

REMARKS

FORMAL MATTERS:

Claims 1-7 and 9-18 are pending after entry of the amendments set forth herein.

Claims 1-6 and 12-18 have been withdrawn.

Claim 8 is canceled without prejudice.

Claims 7 and 9-11 are amended. Support for these amendments is found in original claim 8 and p. 11, lines 1-15 and lines 30-34 of the instant specification.

The specification has been amended on pages 6 in order to address the Examiner's objections regarding the missing character from line 71, i.e., "IFN-□."

No new matter has been added.

OBJECTIONS TO THE SPECIFICATION

The specification at page 6, line 71 has been objected to for missing a character from "IFN-□."

In view of the above amendment, this objection may be withdrawn.

REJECTIONS UNDER §112, ¶1

Claims 7-11 have been rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the enablement requirement.

In making the rejection, the Examiner asserts the following:

The specification while being enabling for anti-HIV-1 activity, CD4 cells primed with DC and R5 suppression, does not reasonably provide enablement for anti-HIV-2 activity, CD4 cells only exposed to HIV and X4 suppression (Office Action, page 2).

In view of the above amendments to claims 7 and 9-11, this rejection may be withdrawn.

CONCLUSION


Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number ORIN-002.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 26, 2006

By:


Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\ORIN002\Amendment in Response to OA 5.3.06.doc